If your ambition is to excel at the oncology career you have chosen, you have to find your own pathway to success. Anna Wagstaff talked to three early-career oncologists who are trying to do just [more]
With the advent of Open Access – a new publishing model that asks researchers to pay to make their research publicly accessible – unscrupulous predators were granted easy access to a house full of naïve and ingenuous scientists and doctors, and today thrive at their expense, and at the expense of science, including cancer research. [more]
Many patients are being treated with costly new radiotherapy treatments on the basis of hype rather than evidence that they stand to benefit. For others, lack of evidence is delaying access to new treatments that [more]
Brachytherapy, a standard of care for some cancer indications, which involves delivering radiotherapy from a source within the tumour, is underfunded, increasingly marginalised and in decline across much of Europe. Janet Fricker talked to specialists [more]
The lack of women in apical positions is a weakness of oncology, and a loss for patients. Mentorship programs launched in recent years by scientific societies like ESMO and ASCO, together with practical support for [more]
Traditional assumptions about the benefits of higher doses are being challenged as patients demand more emphasis on quality of life and new knowledge emerges about the development of resistance. So why are drug developers still [more]
No cancer cell can survive, thrive, proliferate, infiltrate or metastasise without concerted help from the tumour microenvironment (TME). So shouldn’t treatment strategies aim to modify what’s happening around the cancer as much as directly targeting [more]
Some commonly used statistical concepts are hard to master not only for most patients, but for many professionals as well. Especially when it comes to cancer screening A common assumption, when addressing informed decision making [more]
After 25 years of trying to improve the way we organise and deliver cancer care we now have a fairly clear idea about what changes are needed to get the best patient outcomes. Finding ways [more]
Should regulators insist on robust evidence that a new drug shows clear benefit to patients as a condition of approval, or are demands for such levels of certainty unrealistic, or even unethical? Marc Beishon reports [more]
European Reference Networks can only work if member states designate and develop their own accredited specialist centres that can network across borders. Simon Crompton talks to some of the policy makers, clinicians and patient advocates [more]
With the prospect of a chemo-free cure for some blood cancers, and with new targets and new drugs emerging at an unprecedented pace, Simon Crompton asks: Is haematology where the promise of precision medicine will [more]
Uncontrolled pain can blight the lives of cancer patients and survivors. But all too often, health professionals don’t ask, and patients don’t tell. Simon Crompton looks at why this is still the case, and what [more]